10-K: Renalytix Achieves Key Milestones, Eyes Profitability in Two Years

Renalytix reports significant progress in commercializing its KidneyIntelX test, including FDA authorization, Medicare coverage, and cost reductions, projecting profitability within two years.

Summary

• Renalytix has developed KidneyIntelX, an FDA-authorized in-vitro diagnostic test for assessing the risk of progressive kidney function decline in adults with type 2 diabetes and early-stage kidney disease.
• The test received formal Medicare coverage in June 2024 at $950 per test and has also secured coverage from several major insurance plans.
• The addressable market for KidneyIntelX in the US is approximately 14 million patients, with a global market estimated at 260 million patients.
• KidneyIntelX was included as a risk assessment tool in the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
• The company has completed operational restructurings, resulting in a 60% reduction in cash-burn rate and a 50% reduction in overhead.
• Management believes the company can achieve financial break-even status in two years.
• An equity financing expected to close in October 2024 is projected to increase balance sheet cash by approximately $14 million.
• Real-world evidence data shows that use of KidneyIntelX was associated with clinical actions that led to a significant slowing of chronic kidney disease progression and improved Type 2 diabetes control.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant achievements in regulatory approvals, reimbursement, and cost reductions. However, the company still faces risks related to funding, competition, and market adoption, which temper the overall sentiment.

Positives

• KidneyIntelX is the first FDA-authorized in-vitro prognostic test for kidney disease progression.
• The test has received Medicare coverage and is included in clinical guidelines.
• The company has achieved significant cost reductions and is on track to reach profitability.
• Real-world evidence supports the clinical utility and positive impact of KidneyIntelX.
• The company is expanding its commercial reach through partnerships with healthcare systems.
• The company has a large and growing addressable market for its technology.

Negatives

• The company has incurred significant losses since its inception.
• The company's future capital needs are uncertain.
• The company is reliant on a limited number of suppliers.
• The company faces competition from larger diagnostic companies.
• The company's ability to be profitable depends on successful commercialization and scaling of KidneyIntelX.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• Failure to execute on partnerships with healthcare systems could significantly reduce revenue prospects.
• The company's artificial intelligence-enabled algorithms depend on building a substantial data repository.
• Modifications to products may require new regulatory clearances or approvals.
• The company's commercial success depends on obtaining and maintaining adequate reimbursement from third-party payors.
• The company is reliant on a limited number of suppliers.
• The company's long-term strategy depends on improving KidneyIntelX to keep pace with advances in technology and medicine.
• The company may not be able to obtain and maintain sufficient patent protection for its products.
• The trading price of the company's ADSs and ordinary shares may be volatile.
• The company has announced the delisting of its ADSs from trading on the Nasdaq Capital Market, which could limit investors' ability to make transactions in its ADSs and subject it to additional trading restrictions.
• The company has identified a material weakness in its internal controls over financial reporting.

Future Outlook

Management believes the company can achieve financial break-even status in two years and that the recent equity financing should provide adequate resources to significantly grow testing adoption and revenues and cover operating costs through to profitability.

Management Comments

• Management believes all major elements are in place to support continued sequential annual revenue growth.
• Management is now completing the restructuring of the cost structure of the company.
• Management believes the Company can achieve financial break-even status in two years.

Industry Context

The document highlights the growing global burden of chronic kidney disease and the need for preventative medicine, positioning KidneyIntelX as a solution for early risk assessment and intervention. The inclusion of KidneyIntelX in the KDIGO guidelines underscores its importance in the clinical management of CKD.

Comparison to Industry Standards

• The document positions KidneyIntelX as a first-in-class, AI-enabled prognostic test, differentiating it from existing methods for risk stratification of patients with CKD, which lack sufficient precision in predicting progressive kidney function decline, especially at earlier stages of the disease.
• The document mentions that other methods for risk stratification of patients with CKD lack sufficient precision in predicting progressive kidney function decline, especially at earlier stages of the disease, and that up to 38% of patients with CKD initiate dialysis with little or no prior clinical specialist consultation, and up to 63% of patients with CKD initiate dialysis in an unplanned fashion with a central venous catheter and/or during emergency hospitalization.
• The document also states that the KDIGO classification system has been shown in practice to lack sufficient precision to predict who will experience rapid and sustained progression in kidney function decline, especially in earlier stages of DKD (Stages 1 through 3).
• The document compares KidneyIntelX to existing tests used in the kidney space, such as serum creatinine or Cystatin C, which only provide information on the current status of kidney function through an estimation of eGFR, while KidneyIntelX provides a prognostic assessment of risk for kidney disease progression.
• The document also mentions that several large diagnostic laboratories and manufacturers, such as Quest Diagnostics, LabCorp, ThermoFisher Scientific, Danaher Corporation, Roche Holding AG, Abbott Laboratories, Bio-Rad Laboratories, Inc., Ortho Clinical Diagnostics NV and Siemens Healthineers AG, have widespread brand recognition and market penetration and substantially greater financial, technical, research and development and selling and marketing capabilities than Renalytix, but none of these companies currently offer tests that are comparable to kidneyintelX.dkd.

Related Party Transactions

• The company has a license agreement with Mount Sinai Health System, which is a related party.
• The company has a license agreement with Joslin Diabetes Center, which is a related party.
• The company has a partnership with Atrium Health, Wake Forest Baptist Health and Wake Forest School of Medicine, which are related parties.
• The company has a relationship agreement with Mount Sinai Health System and NPLUS1 Singer Advisory LLP.
• The company has a securities purchase agreement with an institutional investor, which is a related party.
• The company has a placing agreement with Stifel Nicolaus Europe Limited, which is a related party.
• The company has a bond agreement with CVI Investments, Inc., which is a related party.

Stakeholder Impact

• Shareholders: The company's progress towards profitability and revenue growth is positive for shareholders, but they face risks related to dilution and market volatility.
• Employees: The company's restructuring and cost reductions may impact employees, but the potential for growth and profitability could provide long-term benefits.
• Customers: Healthcare providers and patients will benefit from the availability of KidneyIntelX as a tool for early risk assessment and intervention.
• Suppliers: The company's reliance on a limited number of suppliers poses a risk to the supply chain.
• Creditors: The company's debt restructuring and potential for profitability may improve its creditworthiness.

Next Steps

• Continue to build partnerships with healthcare systems to optimize direct to physician promotion.
• Further expand insurance payor coverage.
• Build a repository of kidney disease-related data.
• Expand the product portfolio.
• Continue the Real World Evidence Program.
• Launch in major international markets.

Key Dates

Keywords

KidneyIntelX, chronic kidney disease, diabetic kidney disease, FDA authorization, Medicare coverage, artificial intelligence, prognostic test, commercialization, healthcare systems, reimbursement, clinical guidelines